Latest revenue
—
as of 2025-12-31
Latest net income
$-206.7M
as of 2025-12-31
Net margin
—
as of 2025-12-31
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Pharmaceutical Preparations (528 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 6, 2026.
Community sentiment
Where do you think ANNX is heading?
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $203.8M
- Enterprise value
- $28.6M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- 1.00×
- Dividend yield
- 0.0%
- 52-wk high
- $7.18
- 52-wk low
- $1.85
- Beta
- —
- Shares out
- 38.6M
5-year trend
What this company does
Item 1. Business. In this Annual Report on Form 10-K, “we,” “our,” “us,” “Annexon” and the “Company” refer to Annexon, Inc. and its consolidated subsidiary. Annexon, Annexon, Inc., the Annexon logo and other trade names, trademarks or service marks of Annexon are the property of Annexon, Inc. This report contains references to our trademarks and to trademarks belonging to other entities. Trade names, trademarks and service marks of other companies appearing in this report are the property of their respective holders. We do not intend our use or display of other companies’ trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies.…
AI summary unavailable — showing raw filing excerpt
Generated from ANNX's filing dated 2026-03-30
Key risks
Item 1A. Risk Factors. Our business involves significant risks, some of which are described below. You should carefully consider the risks and uncertainties described below, together with all of the other information contained in this Annual Report on Form 10-K, including "Management's Discussion and Analysis of Financial Condition and Results of Operations" and the financial statements and the related notes. If any of the following risks actually occur, it could harm our business, prospects, results of operations and financial condition and future prospects. In such event, the market price of our common stock could decline and you could lose all or part of your investment. Additional risks…
AI summary unavailable — showing raw filing excerpt
Generated from ANNX's filing dated 2026-03-30
Profitability
Return on equity
-97.7%
107.1%Return on assets
-74.5%
88.6%Leverage
Debt / equity
0.31×
60.3%Debt / assets
23.7%
45.9%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | — | — | $-44.1M | +18.8% | — |
Q4 2025 2025-12-31 | — | — | $-48.3M | +0.7% | — |
Q3 2025 2025-09-30 | — | — | $-54.9M | -57.7% | — |
Q2 2025 2025-06-30 | — | — | $-49.2M | -66.0% | — |
Q1 2025 2025-03-31 | — | — | $-54.4M | -115.9% | — |
Q4 2024 2024-12-31 | — | — | $-48.6M | — | — |
Q3 2024 2024-09-30 | — | — | $-34.8M | -7.2% | — |
Q2 2024 2024-06-30 | — | — | $-29.6M | +15.9% | — |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Pharmaceutical Preparations · SIC 2834
Your notes
Keep private notes on ANNX — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$9.0M
Insider selling
$321.4K
Net activity
+$8.7M
Distinct insiders
8
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns ANNX
Institutional value
$198.0M
Total shares held
36.6M
Distinct holders
102
-64 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 10.9M | $60.6M | +2.0M (+22.1%) | Added |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 6.0M | $33.0M | — | New |
| 3 | Nuveen, LLC | 4.2M | $23.5M | +1.3M (+45.7%) | Added |
| 4 | VANGUARD PORTFOLIO MANAGEMENT LLC | 1.5M | $8.2M | — | New |
| 5 | Y-Intercept (Hong Kong) Ltd | 1.3M | $7.3M | — | New |
| 6 | UBS Group AG | 1.2M | $6.9M | +868.8K (+230.4%) | Added |
| 7 | DIMENSIONAL FUND ADVISORS LP | 924.1K | $5.1M | +205.4K (+28.6%) | Added |
| 8 | KENNEDY CAPITAL MANAGEMENT LLC | 912.3K | $5.1M | +272.4K (+42.6%) | Added |
| 9 | VANGUARD FIDUCIARY TRUST CO | 888.6K | $4.9M | — | New |
| 10 | Invesco Ltd. | 763.0K | $4.2M | -209.4K (-21.5%) | Trimmed |
| 11 | Russell Investments Group, Ltd. | 711.4K | $3.9M | +28.4K (+4.2%) | Added |
| 12 | WELLS FARGO & COMPANY/MN | 698.7K | $3.9M | +125.0K (+21.8%) | Added |
| 13 | Ensign Peak Advisors, Inc | 625.1K | $3.5M | — | New |
| 14 | DEUTSCHE BANK AG\ | 562.2K | $3.1M | +1.4K (+0.3%) | Added |
| 15 | Board of Trustees of The Leland Stanford Junior University | 482.6K | $2.7M | +0 (+0.0%) | No change |
| 16 | MUTUAL OF AMERICA CAPITAL MANAGEMENT LLC | 416.7K | $2.3M | -225.3K (-35.1%) | Trimmed |
| 17 | Bank of New York Mellon Corp | 395.0K | $2.2M | +33.3K (+9.2%) | Added |
| 18 | JPMORGAN CHASE & CO | 323.9K | $1.6M | +270.2K (+502.8%) | Added |
| 19 | BNP PARIBAS FINANCIAL MARKETS | 255.4K | $1.4M | +193.8K (+314.8%) | Added |
| 20 | Swiss National Bank | 236.0K | $1.3M | — | New |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once ANNX's latest filing finishes processing.
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.